AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04405570
Drug: Molnupiravir 200 mg
RxNorm normalized name: molnupiravir 200 MG
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral capsule of molnupiravir
Trial: NCT04405570
Drug: Molnupiravir 400 mg
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral capsule of molnupiravir
Trial: NCT04649723
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, 600 mg, fasted.
Trial: NCT03213678
Drug: Samotolisib
RxNorm normalized name: Samotolisib
DrugBank: LY-3023414 (DB12167)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04429087
Drug: BI 764532 - parenteral 1
RxNorm normalized name: Bis(1-piperidylthiocarbonyl) disulfide
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BI 764532 - parenteral 1
Trial: NCT04429087
Drug: BI 764532 - parenteral 2
RxNorm normalized name: Bis(2-benzothiazolyl) disulfide
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BI 764532 - parenteral 2
Trial: NCT04405570
Drug: Molnupiravir 800 mg
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral capsule of molnupiravir
Trial: NCT03835715
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8
Trial: NCT01003054
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m\^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
Trial: NCT01422915
Drug: Colestipol
RxNorm normalized name: Colestipol
DrugBank: Colestipol (DB00375)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 grams morning and bedtime for 90 days.
Trial: NCT01024010
Drug: Pentostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04534478
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized 1: 1 between the two arms of the study
Trial: NCT01003054
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is \>1500/mcl and platelets \>50,000 /mcl, may be titrated to maintain ANC \>1.0 and platelets \>50,000 /mcl.
Trial: NCT03340675
Drug: Ifetroban
RxNorm normalized name: Ifetroban
DrugBank: Ifetroban (DB12321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight based, once daily oral ifetroban
Trial: NCT03455491
Drug: XC221 100 mg
RxNorm normalized name: XC221
DrugBank: XC221 (DB16503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily during 3 days.
Trial: NCT03455491
Drug: XC221 200 mg
RxNorm normalized name: XC221
DrugBank: XC221 (DB16503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily during 3 days.
Trial: NCT04218851
Drug: Posaconazole IV
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole (POS) 6 mg/kg body weight by IV infusion
Trial: NCT04218851
Drug: Posaconazole PFS
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosing based on weight-band taken orally
Trial: NCT04218851
Drug: Posaconazole tablet
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: POS tablet 300 mg taken orally
Trial: NCT02086786
Drug: Risperidone ISM
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals.
Trial: NCT00964535
Drug: budesonide and formoterol 200/6 microg
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 inhalations as a single dose
Trial: NCT00964535
Drug: budesonide and formoterol 200/6 microg
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 inhalations as a single dose with the concurrent charcoal blockage
Trial: NCT00081237
Drug: OSI-7904L
RxNorm normalized name: OSI-7904L
DrugBank: OSI-7904L (DB05457)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00081237
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00251940
Drug: Tesaglitazar 0.5 or 1 mg
DrugBank: Tesaglitazar (DB06536)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00135668
Drug: Nitroprusside
RxNorm normalized name: Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS (Interactive Voice Response System).
Trial: NCT00135668
Drug: Nitroprusside
RxNorm normalized name: Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
Trial: NCT00135668
Drug: Nitroprusside
RxNorm normalized name: Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS
Trial: NCT02586935
Drug: Tideglusib
RxNorm normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
Trial: NCT00949546
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: etanercept 50 mg sc twice weekly
Trial: NCT00704353
Drug: Ferric Carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
Trial: NCT01136655
Drug: 40 μg budesonide HFA pMDI
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: inhalation
Trial: NCT02752516
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Trial: NCT01863745
Drug: nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib was administered daily as hard gelatin capsules for oral use. The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
Trial: NCT03195088
Drug: BI 473494
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT04496401
Drug: Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase 1: standard dose and frequency tacrolimus, used in accordance with licensing and local protocols. Suitable target trough level should be between 7-14 ng/ml.~Phase 2: ENVARSUS® (LCP Tacro - extended release tacrolimus), used once-daily at an initial dose of 0.17mg/kg, dose adjusted to maintain an appropriate therapeutic blood concentration (measured by trough level). Suitable target trough level should be between 7-14 ng/ml.
Trial: NCT00768521
Drug: tolterodine tartrate
RxNorm normalized name: Tolterodine Tartrate
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule
Trial: NCT00768521
Drug: Comparator: Placebo to tolterodine tartrate
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule
Trial: NCT02937818
Drug: Durvalumab and Tremelimumab
RxNorm normalized name: tremelimumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
Trial: NCT02937818
Drug: AZD1775 and carboplatin (CBPT)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
Trial: NCT02937818
Drug: AZD6738 and olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
Trial: NCT02287623
Drug: liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive a tap with liposomal bupivacaine
Trial: NCT02287623
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive a tap with bupivacaine
Trial: NCT00407394
Drug: Amoxycillin
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00892892
Drug: Rilmenidine
RxNorm normalized name: Rilmenidine
DrugBank: Rilmenidine (DB11738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg Rilmenidine per day versus
Trial: NCT03742505
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single enteral cholecalciferol load at a dose of 10,000 IU/kg (maximum 400,000 IU)
Trial: NCT00892892
Drug: Nitrendipine
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Nitrendipine per day
Trial: NCT02755311
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin (Bristol-Myers Squibb, New York, NY).
Trial: NCT02755311
Drug: lipiodol
RxNorm normalized name: Lipiodol
DrugBank: Ethiodized oil (DB00965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).
Trial: NCT03982004
Drug: Topical imiquimod
RxNorm normalized name: imiquimod Topical Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will apply the cream directly over the treatment areas and can use up to one packet per day (covers approximately 5 cm x 5 cm).
Trial: NCT03982004
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion
Trial: NCT00442052
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00442052
Drug: omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02702765
Drug: Galactose
RxNorm normalized name: Galactose
DrugBank: Galactose (DB11735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galactose elimination capacity is performed to evaluate metabolic liver function.~The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours.
Trial: NCT01505790
Drug: PRASUGREL
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60 mg the first day then 10 mg per day during one month
Trial: NCT01505790
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg clopidogrel will be administered during the first 6 to 12 hours then a measure of platelets reactivity will be done. An additional administration of clopidogrel (600 mg) could be done every 6 hours until to obtain a VASP \<50%. No more than 3 \* 600mg of clopidogrel will be authorized in this protocol.~Then for patient which have received more than one dose of clopidogrel 600mg , 150 mg per day of clopidogrel will be administrated, for which who have received only one dose of 600mg of clopidogrel , 75 mg per day will be administrated during one month at least.
Trial: NCT04173676
Drug: Indocyanine Green for Injection
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The sentinel lymph nodes were observed by submucosal injection of ICG
Trial: NCT00263029
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60mg/m² as a 2-hour intravenous infusion every week for 5-6 week
Trial: NCT01289236
Drug: milnacipran
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period
Trial: NCT01289236
Drug: Milnacipran
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.
Trial: NCT03161054
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).~Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).~Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).
Trial: NCT00821080
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Taken orally at different dose levels depending upon enrollment time period
Trial: NCT00821080
Drug: Vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally at different dose levels depending upon enrollment time period
Trial: NCT00427076
Drug: Cotrimoxazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR\< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR\<30.
Trial: NCT00427076
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR \<10 1gr Q 4-7 days.
Trial: NCT01268358
Drug: Lamazym
RxNorm normalized name: Lamazym
DrugBank: Velmanase alfa (DB12374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamazym, ERT, infusion weekly
Trial: NCT01744665
Drug: nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
Trial: NCT01981655
Drug: 0.5M Sodium lactate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A bolus of 0.5M Sodium lactate of 3 ml per kg BW is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
Trial: NCT03034564
Drug: Northera
RxNorm normalized name: Northera
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01411436
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who have received Nexavar for unresectable HCC
Trial: NCT01673711
Drug: laboratory biomarker analysis
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Correlative studies
Trial: NCT01859728
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics.
Trial: NCT01859728
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics.
Trial: NCT01859728
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.~Given in association with standard hydration and anti-emetics.
Trial: NCT01859728
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics.
Trial: NCT02676089
Drug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00940693
Drug: duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg capsule once per day for 6 weeks
Trial: NCT00610987
Drug: cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours.
Trial: NCT03028571
Drug: Trimethaphan
RxNorm normalized name: trimethaphan
DrugBank: Trimethaphan (DB01116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethaphan 4 mg/min IV will be given as a pharmacological tool to study the role of the autonomic nervous system on the regulation of endogenous glucose production by the liver.
Trial: NCT03075527
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.
Trial: NCT03075527
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.